Aptorum : Corporate Presentation - English (Jan 2022)

Facilitating Life Science Innovations to Serve Unmet Medical Needs

CORPORATE PRESENTATION

NASDAQ GLOBAL MARKET: APM

Disclaimer

This document includes statements concerning Aptorum Group Limited and its future expectations, plans and prospects that constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein that are not statements of historical fact may be deemed to be forward-looking statements. In some cases, you can identify forward-looking statements by terms such as "may," "should," "expects," "plans," "anticipates," "could," "intends," "target," "projects," "contemplates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of these terms or other similar expressions. Aptorum Group has based these forward-looking statements, which include statements regarding projected timelines for application submissions, trials and commercialization and market potential of related products, largely on its current expectations and projections about future events and trends that it believes may affect its business, financial condition and results of operations. These forward-looking statements speak only as of the date of this document and are subject to a number of risks, uncertainties and assumptions including, without limitation, risks related to its announced management and organizational changes, the continued service and availability of key personnel, its ability to expand its product assortments by offering additional products for additional consumer segments, development results, the company's anticipated growth strategies, anticipated trends and challenges in its business, and its expectations regarding, and the stability of, its supply chain, and the risks more fully described in Aptorum Group's Form 20-F and other filings that Aptorum Group may make with the SEC in the future. As a result, the projections included in such forward-looking statements are subject to change and results may differ materially from those disclosed herein. Aptorum Group assumes no obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

2

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.

© Copyright 2022 Aptorum Group Limited

About Aptorum Group

Company Information

• Established in 2010, Aptorum is a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology, auto-immune and infectious diseases.
• Business Strategy: from Discovery to Phase II Proof-of-Concept (PoC).
• Markets and Regulatory: targeted for clinical and market approval by US FDA, China NMPA, Europe EMA and regulatory authorities in other major countries.
• IPO: listed on NASDAQ Global Market (ticker symbol: APM) since December 18, 2018 and cross-listed on Euronext
  Paris (ticker symbol: APM) since July 24, 2020.
• Company's principal executive office is based in London, United Kingdom
• Development of key products in partnership with North America based CROs (US and Canada), including GLP studies, GMP manufacturing and clinical trials coordination.
• Completion of Phase I clinical trials for 2 therapeutic drugs ALS-4 (MRSA) and SACT-1 (Neuroblastoma), Clinical validation phase for RPIDD (liquid biopsy infectious disease molecular diagnostics) and Commercialization stage for NLS-2 (Nativuswell), a Women's menopause supplement product.

3

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.

© Copyright 2022 Aptorum Group Limited

Directors, Management and Significant Employees

Leadership

Mr. Ian HUEN

Founder, Chief Executive Officer and Executive Director

• Over 18 years in global asset management;
• US healthcare equity research analyst at Janus Henderson Group;
• Trustee board member of Dr. Stanley Ho Medical Development Foundation;
• CFA, Princeton University, U.S. (Econ)

MR. Darren LUI

President and Executive Director

• Over 15 years in global capital market;
• Director of Structured Capital Markets at Barclays Capital.;
• Chartered Accountant (ICAS), Chartered Financial Analyst & Associate of Chartered Institute of Securities & Investments (UK);
• First-ClassHonors from Imperial College (Biochemistry)

DR. Clark CHENG

Chief Medical Officer and Executive Director

• Almost 10 years working in Raffles Medical Group as Operations Director and Deputy General Manager;
• Received medical training at the University College London in 2005 & obtained membership of the Royal College of Surgeons of Edinburgh in 2009;
• MBA, University of Iowa, U.S.

MISS Sabrina KHAN

Chief Financial Officer

• Over 10 years serving US & Asian healthcare companies;
• Extensive experience in business development, restructuring, US & Asian IPO, and M&A deals;
• Chartered Accountant at Ernst & Young LLP;
• Advanced China Certified Taxation Consultant;
• CPA, University of Hong Kong (BBA(Acc & Fin))

DR. Thomas LEE Wai Yip

Head of Research and Development

• Former Assistant Professor at The Chinese University of Hong Kong (CUHK) specialized in drug delivery and formulation development;
• 10 years from Novartis & Celgene;
• B.Pharm.(Hons), CUHK; Ph.D. in Pharmaceutical Sciences (Drug Delivery), the University of Wisconsin-Madison

Independent Non-Executive Directors

PROFESSOR	DR.	DR.	MR. Charles
Douglas ARNER	Justin WU	MIRKO SCHERER	BATHURST
Kerry Holdings Professor in	COO of CUHK Medical	CEO of CoFeS China and Ex	Founder of Summerhill
Law, HKU	Centre	Head of TVM Asia	Advisors Limited

4

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.

© Copyright 2022 Aptorum Group Limited

DR. Keith CHAN

Consultant

• Adjunct professor and advisor at the Research Center for Drug Discovery, National Yang Ming University in Taipei;
• Former Division Director of Office of Generic Drugs, US FDA;
• Co-founderof Globomax LLC;
• Formerly employed at Ciba-Geigy

Aptorum Team

Consultants and Advisors to Aptorum Group and Subsidiaries

	DR. Nishant		DR. Lawrence		DR. Francis SZELE
	AGRAWAL		BAUM		Senior Scientific Advisor
	Senior Clinical Advisor		Senior Scientific Advisor
•	Professor of Surgery, School of Medicine, University	•	Asso. Professor, School of Pharmacy, The Chinese	•	Asso. Professor, Department of Physiology,
	of Chicago;		University of Hong Kong;		Anatomy & Genetics, University of Oxford;
•	Former Asso. Professor at Johns Hopkins	•	Research Officer, Faculty of Medicine, The	•	Asst. Professor, Subventricular Zone, Northwestern
	University;		University of Hong Kong;		University;
•	M.D., Johns Hopkins University School of Medicine	•	Ph.D. in Neurosciences, UC San Diego	•	Ph.D. in Biology, The University of Pennsylvania,
					U.S.

MR. William WEISS

Consultant

• Currently Director of Preclinical Service and Instructor of Pharmaceutical Sciences, College of Pharmacy, University of North Texas;
• 38 years of experience in drug discovery and development of antimicrobials including antibiotics, antivirals and antifungals;
• Former Director of Cumbre Pharmaceuticals Inc;
• Former Group Leader at Wyeth for 17 years;
• Formerly employed at Schering-Plough for 7 years;
• BSc in Microbiology from Rutgers University; MSc in Microbiology from Penn State University and Fairleigh Dickinson University

DR. Kira SHEINERMAN

Senior Strategic Consultant

• Co-Founder,CEO and Executive Director of DiamiR Biosciences;
• Serves as a Managing Director, Healthcare Investment Banking at H.C. Wainwright & Co.;
• Ph.D. in Biomedical Sciences from Mount Sinai School of Medicine in New York;
• Honors MBA from Zicklin School of Business, Baruch College, City University of New York

DR. Robbie MAJZNER

Advisor

• Assistant professor of Pediatrics (Hematology/Oncology) at the Stanford University Medical Center;
• Completed residency training in pediatrics and fellowship training in pediatric hematology-oncology;
• Board certified in pediatrics and pediatric hematology-oncology;
• M.D., Harvard Medical School

5

For illustrative purposes only. There is no guarantee of any project being completed or having a specific outcome.

© Copyright 2022 Aptorum Group Limited